IRCT20200317046797N1招募中3 期
Effect of Camostate mesylate on clinical improvement and outcome of Coronavirus (COVID-19)-induced pneumonia
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Moderate to severe 2019-nCoV-infected patients
- •Being at the age of 18 to 80 years
- •Patients or authorized family members volunteered to participate in this study and signed informed consent.
- •Both genders
- •pulmonary involvement in CT scan
- •PCR positive
排除标准
- •Patient with elevated liver enzymes 3 time the upper limit of normal
- •Patients who are participating in other drug clinical trials
- •Patients with active pulmonary tuberculosis
- •Patients with definite bacterial and fungal infections
- •Pregnant or lactating women
- •Patient with active thrombotic event
研究者
相似试验
撤回
1 期
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsCardiovascular ComplicationCOVID-19CoagulopathyNCT04435015Yale University
已完成
1 期
Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy VolunteersHealthyNCT04782505Daewoong Pharmaceutical Co. LTD.61
已完成
2 期
Camostat Mesylate in COVID-19 OutpatientsCOVID-19NCT04353284Yale University70
尚未招募
2 期
Evaluation of Clemastine effects in CTS pateintsCarpal tunnel syndromeIRCT20190428043404N2Iran University of Medical Sciences20
招募中
1 期
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT06431243Chengdu Zenitar Biomedical Technology Co., Ltd132